• IMS Health’s Integrated Cancer Access Solutions (ICAS) 

    Meet the process and timeline challenges for the new English cancer drugs ecosystem

Ensure a Positive NICE Appraisal

IMS Health’s Integrated Cancer Access Solutions (ICAS) can support you throughout the NICE Cancer appraisal process:

Enable NICE to Make a Final Positive Decision Following Your Two Year Data Collection

In case your drug is exposed to ‘conditional access’ through the Cancer Drugs Fund (CDF), IMS Health’s Integrated Cancer Access Solutions allows you to:

  • Identify the patient level data required
  • Build the pricing strategy to submit to the NHS England/NICE Managed Access Investment Group
  • Deliver an RWE study that will provide full confidence around the areas of clinical uncertainty to NICE, NHSE, Patients and clinicians

Make Informed Decisions so Patients in England Can Have Unfettered Access to Cancer Drugs

Interested in learning more about how IMS Health's Integrated Cancer Access Solutions (ICAS) can help you succeed? Let us know how we can help you:


*Required